

2024 AGM Results

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) advises that the 2024 Annual General Meeting of the Company was held today, Wednesday 20 November 2024, commencing at 12pm AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

The Board thanks shareholders for their ongoing support.

- ENDS -

Authorised for release by the Board.

For further information contact us via investor@rhythmbio.com:

Dr David Atkins Managing Director and Chief Executive Officer	Ms Andrea Steele General Counsel & Joint Company Secretary
---	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The Company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the Company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable. The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Trevor Lockett
Louis Panaccio
David Atkins

Non-Executive Chairman
Non-Executive Deputy Chair
Non-Executive Director
Non-Executive Director
CEO & Managing Director



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to the resolutions put to members at the meeting, which were **decided on a Poll**.

	Resolution	Proxy Votes						Poll			Result
		For	Against	Open	Exclusions	Abstain	Total	For	Against	Abstain	Carried / Not Carried
Resolution 1	ADOPTION OF REMUNERATION REPOR	31,784,023	28,002,001	3,418,245	43,141,875	22,240	106,346,144	38,610,616	28,155,501	22,240	Carried First Strike
		50.29%	44.30%	5.41%				57.83%	42.17%		
Resolution 2	RE-ELECTION OF MS SUE MACLEMAN	75,425,637	27,699,638	3,394,909	-	55,200	106,520,184	82,828,217	27,253,815	55,200	Carried
		70.81%	26.00%	3.19%				75.24%	24.76%		
Resolution 3	ELECTION OF DR DAVID ATKINS	94,829,446	8,208,493	3,438,245	-	4,200	106,476,184	100,829,539	9,208,493	4,200	Carried
		89.06%	7.71%	3.23%				91.63%	8.37%		
Resolution 4	APPROVAL OF 10% PLACEMENT FACILITY (Special Resolution)	92,867,519	9,756,603	3,459,245	-	221,017	106,083,367	100,334,435	9,310,780	221,017	Carried
		87.54%	9.20%	3.26%				91.51%	8.49%		